Diabetes drug halves risk of heart failure

The effect appears consistent in patients with or without CVD, a real-world study shows
Clare Pain

Patients with type 2 diabetes (with and without cardiovascular disease) who are taking empagliflozin have half the risk of being hospitalised for heart failure compared with similar patients on sitagliptin, a US study shows.

In the first interim report from the real-world study EMPRISE, Harvard University researchers analysed three large patient databases and matched patients with type 2 diabetes who had recently started the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin with those who had recently been prescribed the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin.